Active Ingredient History

  • Now
Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta.   Wikipedia

  • SMILES: [Na+].COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C
  • Mol. Mass: 381.43
  • ALogP: 2.99
  • ChEMBL Molecules:
More Chemistry
al-3810 | co-3810 | e-3810 | lucitanib | s-80881


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue